Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio reported that the European Commission has granted conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) plus BCG to treat adults with BCG‑unresponsive non‑muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.
This decision makes ANKTIVA the first immunotherapy authorized in Europe for this high‑risk bladder cancer setting and extends availability across all 27 EU member states plus Iceland, Norway, and Liechtenstein, bringing total country coverage to 33. Approval is based on the QUILT‑3.032 trial, which showed a 71% complete response rate, a median complete response duration of 26.6 months, and cystectomy‑free survival among responders of 96% at 12 months and 84% at 36 months.
The authorization is conditional and requires ImmunityBio to submit long‑term safety and efficacy data and renew the authorization annually, while the company pursues pricing, reimbursement, and patient access across Europe.
ImmunityBio, Inc. insider activity: Patrick Soon-Shiong and affiliated entities reported equity award vesting and related share movements. On February 10, 2026, 274,122 restricted stock units were converted into an equal number of ImmunityBio common shares at an exercise price of $0.00. To cover tax obligations on this vesting, 118,560 common shares were withheld at a price of $6.93 per share. Following these transactions, Soon-Shiong directly held 29,701,752 common shares. The filing also lists very large indirect holdings through entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile and NantCancerStemCell, over which he is described as having varying degrees of voting and dispositive power.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported RSU vesting and related share withholding. On February 10, 2026, 82,236 restricted stock units converted into 82,236 shares of common stock at an exercise price of $0, increasing his directly held common stock to 322,818 shares.
On the same date, 42,643 common shares were disposed of at $6.93 per share to cover tax obligations tied to the RSU vesting, leaving him with 280,175 common shares held directly after these transactions. Following the vesting, he also held 164,474 RSUs directly.
ImmunityBio, Inc.’s Chief Accounting Officer, Regan J. Lauer, reported RSU vesting and related share movements. On February 10, 2026, 5,482 restricted stock units were converted into 5,482 shares of common stock at an exercise price of $0, increasing directly held common shares to 115,740.
On the same date, 2,257 common shares were withheld at $6.93 per share to cover tax obligations tied to the vesting, leaving 113,483 common shares held directly after the withholding. Following these transactions, Lauer also directly held 10,965 restricted stock units, which vest over three years starting from a February 10, 2025 commencement date.
ImmunityBio, Inc. executive Richard Adcock, the CEO and President, reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 10, 2026, 274,122 RSUs were converted into the same number of common shares at an exercise price of $0, reflecting vesting of a prior RSU grant.
To cover tax obligations from this vesting, 140,048 common shares were withheld and disposed of at a price of $6.93 per share. After these transactions, Adcock beneficially owned 485,465 shares of ImmunityBio common stock directly, along with 548,246 RSUs that remain outstanding as derivative securities. The RSU award vests over three years from a vesting commencement date of February 10, 2025, contingent on continued service.
ImmunityBio, Inc. entered into a material definitive agreement by amending its existing convertible Second Amended and Restated Promissory Note with Nant Capital, LLC, which has an outstanding principal amount of $505.0 million.
The January 23, 2026 letter amendment changes the note to allow the holder, an entity affiliated with Executive Chairman Dr. Patrick Soon-Shiong, to convert any portion of the outstanding principal into fully paid and nonassessable shares of ImmunityBio common stock at any time before the note’s maturity date. Previously, the December 10, 2024 version of the note did not permit partial conversions.
The company confirms that no other terms of the convertible promissory note were changed by this amendment.
ImmunityBio, Inc. director Simon Barry J. reported two open-market sales of common stock. On January 20, 2026, he sold 76,967 shares at $6.54 per share and 75,000 shares at a weighted average price of $7.8791 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. Following the reported sales, he directly beneficially owned 3,091,604 shares of ImmunityBio common stock.
ImmunityBio, Inc. director Christobel Selecky reported option exercises and share sales in January 2026. On January 16, 2026, she exercised 50,000 stock options with a $2.98 exercise price for common stock and then sold 50,000 shares at $5.00 per share, leaving her with no directly held common stock after the sale. On January 20, 2026, she exercised an additional 25,000 stock options at $2.98 and sold 25,000 shares at a weighted average price of $7.50 to $7.52, again ending with no directly held common shares.
The Form 4 shows that after these transactions, she continued to hold stock options, with 117,937 options remaining after the first exercise and 92,937 options after the second. All of the option shares had fully vested on June 12, 2023, and the options are scheduled to expire on June 14, 2032. The filing notes that the reported sales were made under a Rule 10b5-1 trading plan that she adopted on June 12, 2025, indicating the transactions were pre-arranged rather than opportunistic.
A shareholder of IBRX has filed a Form 144 notice for a proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ market. The filing lists an aggregate market value of $138,000 for these shares and an approximate sale date of 01/20/2026.
The shares to be sold were acquired on 01/20/2026 by exercising stock options granted by the issuer, with cash used as payment for the 25,000 shares. The issuer had 984,965,179 shares outstanding. The filing also discloses that during the prior three months, a Rule 10b5-1 trading plan for Christobel Selecky sold 50,000 common shares for $250,000 in gross proceeds.
A shareholder has filed a Form 144 notice to sell 571,967 shares of common stock through The Charles Schwab Corporation on NASDAQ. The proposed sale has an aggregate market value of $5,909,546.00, with an approximate sale date of 01/20/2026. The filing indicates these shares were acquired from the issuer on 12/31/2013 by various methods and dates, with the full 571,967 shares acquired and paid for on that date. The table also shows that 984,965,179 shares of this class of common stock are outstanding. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.